Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Press Releases
Welcome to our press release archive. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at media@evaluate.com.
Latest Press Releases
2022年 希少疾病用医薬品動向 Evaluate オーファンドラッグ 2022 レポート 日本語版リリース
東京、日本－2022年5月26日 – 製薬業界における戦略策定や事業性評価に不可欠な信頼性の高いマーケット情報及び分析を提供するEvaluate（エバリュエート本社：ロンドン）は、2022年4月に発行した希少疾病用医薬品動向レポート 「オーファンドラッグ 2022 レポート」（原文：英語）の日本語版をリリースしました。
Evaluate appoints Matthew Wright as Chief Financial Officer
London, UK and Boston, MA – 11 May 2022 – Evaluate, a leading provider of market intelligence and predictive analytics for the pharmaceutical industry, has today…
Four prominent pharmaceutical solutions providers launch Norstella to drive innovation and get patients access to life-saving therapies faster
United under Norstella, each brand’s key solutions and expertise will help life-sciences-focused companies get answers—not just insights—from pipeline to patient
Browse the archive
Evaluate Ltd. appoints Martyn Hindley as Chief Financial Officer
Evaluate Ltd., the leading provider of commercial data to the life sciences industry, is pleased to announce the appointment of Martyn Hindley as Chief Financial Officer,…
Evaluate Ltd. transforms pharma R&D risk assessment with launch of Product Specific PTRS
Breakthrough offering combines the power of machine learning with the transparency of Evaluate’s renowned analytical approach for the most accurate analysis of drug…
Evaluate Vantage Half-Year Review 2019: Pharma and medtech mega-deals mask drop in M&A activity
The report, published today, analyses stock and market performance, M&A and the financing landscape during the first half of 2019
Innovation and unmet need drive prescription drug sales to $1.18tr by 2024: new report from Evaluate Ltd
“EvaluatePharma® World Preview 2019, Outlook to 2024” explores growth drivers, growth brakes and top industry performers.
The “one and done” era for orphan drugs: Evaluate predicts 12% growth, driven by new technologies, but benefits go to big pharma
Orphan drug sales reach $242bn by 2024, according to EvaluatePharma® Orphan Drug Report 2019
Biopharma in 2018: A year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong
Evaluate Vantage releases annual analysis of Pharma, Biotech and Medtech performance
Uncertainty for pharma and biotech in 2019 as sector stumbles at the end of 2018
Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2019
Worldwide medtech sales forecast to reach $595 billion by 2024, with a CAGR of 5.6%, anchored by familiar players
Evaluate Ltd. releases annual “EvaluateMedtech World Preview 2018, Outlook to 2024” in conjunction with The Medtech Conference
Small drug developers continue to hold all the cards, while young device makers suffer from a shrinking pool of buyers
Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018
